Pharmacist-led urate-lowering care to reach target in gout patients
Official title: Pharmacist-Led Treat-to-Target Urate Lowering Therapy in Patients in Gout (Pharm-UP) Study
Run by VA Office of Research and Development · NCT06887452 · Data updated 2026-11-12
This study tests whether a pharmacist-led, telehealth approach to ULT management helps veterans with gout reach uric acid goals and reduce flare burden compared with usual care.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 310 (estimated) |
| Sponsor | VA Office of Research and Development Federal |
| Locations | 5 sites (Omaha, Nebraska and 4 other locations) |
| Status | Recruiting |
| Started | October 1, 2026 |
| Main results expected | October 1, 2029 |
| Study ends | March 30, 2031 |
| Registry record updated | October 21, 2026 |
| Trial ID | NCT06887452 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are US veterans with physician-diagnosed gout, hyperuricemia, recent gout flares, and newly prescribed or ongoing urate-lowering therapy, who meet specific dosing and health criteria.
✕Probably not a fit
Patients intolerant to urate-lowering therapies, those with recent rheumatology visits, high-dose CKD (stage IV/V), or life expectancy under 12 months may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The trial compares a pharmacist-led, telehealth-delivered intervention to standard care for US veterans with gout across five VA medical centers. It will enroll about 310 participants and run at multiple sites over 4-5 years, with each participant followed for up to two years. Outcomes include serum urate goal achievement, arthritis flare burden, and patient-reported quality of life and pain impacts. The study aims to quantify the effects of telehealth-guided ULT optimization on clinical and patient-centered outcomes.
Why it matters
Potential benefit: If successful, patients could have better urate control and fewer gout flares through more accessible, pharmacist-driven care.
How similar studies have gone: Prior research suggests collaborative care for gout can improve outcomes, but this specific pharmacist-led telehealth model in veterans is a novel approach needing evaluation.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * US Veterans with physician-diagnosed * Documented hyperuricemia (SU \> 6.8 milligrams per deciliter) * Satisfy American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) gout classification criteria * Report 1 or more flares in the prior 6 months * Receipt of a new urate-lowering therapy (ULT) prescription (allopurinol or febuxostat) initiated by a primary care provider or longer term ULT but otherwise satisfy the flare/SU criteria Exclusion Criteria: * Any patient intolerant or unable to take urate-lowering therapies (allopurinol or febuxostat) * Patients with a rheumatology encounter within the prior 3 months * Patients on an allopurinol dose \> 300 or a Febuxostat dose \> 40 * Patients with stage IV/V Chronic Kidney Disease (CKD) * Patients with a life expectancy \< 12 months * Patients with a concomitant medication of azathioprine or 6-MPC (urate-lowering therapy contraindicated)
Where it's running
-
Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE
Omaha, Nebraska, United States Recruiting -
VA Portland Health Care System, Portland, OR
Portland, Oregon, United States Recruiting -
Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA
Philadelphia, Pennsylvania, United States Recruiting -
VA Salt Lake City Health Care System, Salt Lake City, UT
Salt Lake City, Utah, United States Recruiting -
VA Puget Sound Health Care System Seattle Division, Seattle, WA
Seattle, Washington, United States Recruiting
Study contacts
- Principal investigator: Ted R. Mikuls — Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE
- Study coordinator: Bridget Kramer
- Email: bridget.kramer@va.gov
- Phone: (402) 995-3206
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Dapansutrile tablets for treating acute gout flares
This study is testing if dapansutrile tablets can help people with acute gout flares feel better compared to a placebo.
-
Dotinurad in gout patients who can’t tolerate XOI or failed uricase treatment
This trial tests whether dotinurad can lower uric acid levels in adults with gout who can’t use certain standard medicines or have not benefited from uricase.
-
Orienting project on crystal deposits in gout, CPPD, and osteoarthritis
This project will follow adults with gout or CPPD and people with osteoarthritis to see if crystal deposits in joints and blood vessels change over time and relate to treatments or heart problems.
-
Remote monitoring for gout in primary care
This project will test a smartphone self-management app to help adults with gout and high urate levels manage their condition alongside GP follow-up.
-
Purified Cortrophin® Gel for treating acute gout flares at two dose levels
This study will try two single injections (40 U and 80 U) of Purified Cortrophin® Gel to see which dose better and more quickly reduces pain in adults having an acute gout flare.
-
IV PRX-115 at different dose schedules, with or without methotrexate, versus placebo for adults with gout
This trial will test whether IV PRX-115 given on different schedules, with or without low-dose methotrexate, can lower uric acid and be safe in adults whose gout is not controlled by standard urate-lowering drugs.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.